Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation::Insights from the community-based Darlington atrial fibrillation registry by Mazurek, Michal et al.
 
 
Guideline-adherent antithrombotic treatment
improves outcomes in patients with atrial
fibrillation:
Mazurek, Michal; Shantsila, Eduard; Lane, Deirdre; Wolff, Andreas; Proietti, Marco; Lip,
Gregory
DOI:
10.1016/j.mayocp.2017.05.023
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Mazurek, M, Shantsila, E, Lane, D, Wolff, A, Proietti, M & Lip, G 2017, 'Guideline-adherent antithrombotic
treatment improves outcomes in patients with atrial fibrillation: Insights from the community-based Darlington
atrial fibrillation registry', Mayo Clinic Proceedings, vol. 92, no. 8, pp. 1203-1213.
https://doi.org/10.1016/j.mayocp.2017.05.023
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Mazurek1 
 
Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients with Atrial 
Fibrillation – Insights from the Community-Based Darlington Atrial Fibrillation Registry 
 
Michał Mazurek, PhD,1,2 Eduard Shantsila, PhD,1 Deirdre A Lane, PhD,1 Andreas Wolff, GP,3 
Marco Proietti, MD,1 Gregory Y H Lip, MD1 
 
1 Institute for Cardiovascular Sciences, University of Birmingham, United Kingdom 
2 Department of Cardiology, Congenital Heart Diseases & Electrotherapy, Silesian Centre for 
Heart Diseases, Zabrze, Poland 
3 Division of Family Practice, Chilliwack General Hospital, Chilliwack, British Columbia, 
Canada 
 
Financial support: None.  
Conflict of interest disclosure: 
DAL has received investigator-initiated educational grants from Bayer Healthcare, Bristol 
Myers Squibb and Boehringer Ingelheim, has been a speaker and consulted for Boehringer 
Ingelheim, Bayer, and Bristol Myers Squibb/Pfizer. AW has been a clinical advisor to 
Boehringer Ingelheim, Pfizer, BMS, Sanofi Aventis and Daiichi-Sankyo, also received 
educational grants and investigator payments from the above. In addition served as speaker 
for Boehringer Ingelheim, Sanofi and Pfizer. MP has received consultancy fee from 
Boehringer Ingelheim. GYHL has served as a consultant for Bayer/Janssen, BMS/Pfizer, 
Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Speaker for 
Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. 
ES and MM declare no conflicts of interest. 
Reprints and correspondence:  
Professor GYH Lip  
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Dudley Road, 
Birmingham B18 7QH, United Kingdom  
Tel: +44 121 507 5080; Fax: +44 121 554 4083; E-mail: g.y.h.lip@bham.ac.uk 
 
Mazurek2 
 
Word count of the text: 2996  
Number of references: 32  
Number of tables: 4 
Number of figures: 1 
Number of supplementary figures: 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mazurek3 
 
ABSTRACT 
Objective:  To assess the influence of guideline-adherent versus non-adherent 
antithrombotic treatment (ATT) on stroke and mortality rates in atrial fibrillation (AF)  
primary care population. 
Patients and Methods:  We used Darlington Registry cohort which included 105,000 
patients from March 31, 2012, through March 31, 2013. Guideline-adherence in ATT was 
assessed against 2014 National Institute for Health and Care Excellence (NICE) guidelines, 
which recommend oral anticoagulation (OAC) for stroke prevention as a default 
management unless a truly “low-risk” of stroke (CHA2DS2-VASc=0 in men and 1 in women) is 
evident. 
Results:  Overall, 2259 (2.15%) AF patients were identified, of which 36.1% were under-
treated, 50.8% guideline-adherent and 13.1% over-treated. OAC was declined by 5.0% and 
contraindicated at 8.3%. Overall, 67 (3.0%) incident strokes occurred, of which 66 (98.5%) in 
high-risk patients (CHA2DS2-VASc ≥2). For the high-risk cohort, one-year stroke rates were 
4.5% (95% CI 3.2-6.3) for under-treatment, 1.9% (95% CI 1.2-2.9) for guideline-adherence, 
and 7.2% (95% CI 4.4-11.6) for over-treatment; corresponding mortality rates were 16.1% 
(95% CI 13.6-19.0), 8.0% (95% CI 6.5-9.8), and 8.2% (95% CI 5.2-12.7), respectively. 
On multivariable analysis, both under- and over-treatment of high-risk patients were 
associated with significant increase in stroke rates (OR 2.32, 95% CI 1.30-3.14, P=.005 and 
OR 2.28, 95% CI 1.12-4.63, P=.02, respectively). Under-treatment was also associated with a 
significant increase in all-cause mortality (OR 1.59, 95% CI 1.14-2.21, P=.006).  
Mazurek4 
 
Conclusion:   Only half of eligible AF patients are prescribed OAC in accordance with 
guideline recommendations. Guideline-adherent ATT significantly reduces the risk of stroke 
and improves survival.  
 
Keywords: atrial fibrillation, oral anticoagulation, guideline adherence, stroke, mortality 
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Abbreviations and Acronyms: 
AF = atrial fibrillation; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 
years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 
years, female sex category; CI = confidence interval; EORP-AF = EuroObservational Research 
Programme-Atrial Fibrillation; GRASP-AF = Guidance on Risk Assessment and Stroke 
Prevention in Atrial Fibrillation; NICE = National Institute for Health and Care Excellence; 
NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; OR = odds 
ratio; SD = standard deviation; TTR = time in therapeutic range; UK = United Kingdom 
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Oral anticoagulation (OAC) is the mainstay of effective stroke prevention in atrial fibrillation 
(AF), as reduces both stroke and mortality in AF.1,2 In accordance with current AF guidelines, 
stroke prevention with OAC should be the default therapy in AF patients, unless truly “low-
risk” of stroke, i.e. CHA2DS2-VASc=0 in men and 1 in women, is confirmed.
3,4   
 
Contemporary registry data show that approximately 5% of AF patients have no risk factors 
for stroke,5,6 which indicates that risk stratification and OAC use should be carefully and 
repeatedly reviewed in all AF patients as risk factors can develop over time. Nonetheless, 
approximately one third of AF patients at risk for stroke are not given OAC, but instead are 
treated with antiplatelet monotherapy or left untreated, while approximately 50% of 
patients with no risk factors are unnecessarily prescribed OAC.6,7 
 
Absolute OAC prescription rates, commonly reported by AF studies,8 may be misleading, as 
they may not reflect “real-life” eligibility for anticoagulation by failing to take into account 
the complexity of various clinical and patient-related factors affecting the final decision 
making on OAC prescription. For example, 1 in 10 AF patients refuse to take OAC,9 and the 
same proportion may have contraindications to anticoagulation.10,11 In addition, some AF 
patients may require temporal combination antithrombotic therapy (OAC + antiplatelets) 
due to acute vascular disease.3,4 The definition of guideline adherence may also vary, 
depending on applied stroke risk stratification schemes and guideline recommendations.12,13 
Finally, indication for OAC in individual patients may change over time making comparisons 
even more complex and difficult to interpret. 
 
Previous reports on guideline adherence on OAC for stroke prevention in AF were based 
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predominantly14 or solely15–17 on thromboembolic risk assessment and patients were 
managed by cardiologists, mainly in hospital-based or cardiology outpatient settings, often 
linked to university centers. Moreover, various combined endpoints and selected patient 
populations (i.e. only patients at high-risk for stroke) were used to assess the clinical 
relevance of guideline-recommended antithrombotic therapy.14,16,17   
 
We sought to provide herein a more comprehensive analysis of outcomes related to OAC 
guideline adherence, taking into account the aforementioned clinical and patient factors, 
and to assess the impact of guideline-adherent versus non-adherent thromboprophylaxis on 
“hard” clinical endpoints (stroke and death rates) in an unselected (i.e. consecutive all-
comers) contemporary, community-based AF population. 
 
METHODS 
The design of the Darlington AF Registry has been described previously.18 In short, 11 
primary care practices, serving the population of 105,000 patients from Darlington, County 
Durham, United Kingdom (UK) were involved. Consecutive all-comers with established AF or 
atrial flutter diagnosis and known vital status in March 2013 were eligible for inclusion.  
Each primary care practice was equipped with the Guidance on Risk Assessment and Stroke 
Prevention in Atrial Fibrillation (GRASP-AF) tool.10,18 This electronic record interrogation 
software was designed to support primary care physicians in population-based screening for 
stroke risk factors and facilitate decision making for OAC prescription. Indeed, GRASP-AF is 
free and easy to use tool, which interrogates patient clinical data and allows one to display 
graphically annual stroke risk. This measure helps clinicians identify AF patients who may 
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have a missing diagnosis code for AF, calculate the risk of stroke in patients with AF, identify 
patients at high risk of stroke who are not receiving OAC, calculate the number of strokes 
that a practice can expect in the next twelve months (given current levels of OAC) or help 
clinicians manage their patients with AF and highlight patients of concern or interest.  
As the GRASP-AF tool does not capture outcome events, additional searches of the primary 
care dataset were performed to identify patients who experienced stroke or died during a 
12-month observation period. Incident acute stroke was diagnosed only when there was a 
concordance between clinical picture of cerebrovascular accident, physical examination and 
cerebral imaging (computer tomography or magnetic resonance imaging). Cardiovascular 
death was defined as death resulting from one of the following conditions: cardiac 
(myocardial infarction, cardiac failure, cardiac arrest, coronary heart disease, ventricular 
tachycardia, complete heart block), heart failure, stroke, pulmonary embolism or systemic 
thromboembolism, and intracranial bleeding. Every outcome event was manually reviewed 
and adjudicated.  Read codes were used to capture and identify different types of strokes, 
comorbidities, medical treatment, contraindications to OAC/antiplatelets and therapy 
decline.18 
Stroke Risk 
The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, 
stroke or transient ischemic attack, vascular disease, age 65-74 years, female sex category) 
score was used to assess stroke risk.19 As per the 2014 National Institute for Health and Care 
Excellence (NICE) guidelines, “low-risk” were men with CHA2DS2-VASc=0 and women with 
CHA2DS2-VASc=1 (1 point for sex category only); “moderate-risk” were men with CHA2DS2-
VASc=1; and “high-risk” were patients with CHA2DS2-VASc score ≥2, regardless of sex.
3 
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Guideline Adherence in Antithrombotic Treatment 
Guideline adherence to antithrombotic therapies for stroke prevention was assessed against 
the 2014 NICE guidelines, including an informed, shared decision making on therapy 
introduction.3 Lack of guideline adherence was considered as either over-treatment (OAC 
overuse) or under-treatment (OAC underuse). Thus, our patient categories were defined as 
follows: 
(i) Guideline adherence was defined using the following criteria: 
 OAC in moderate- and high-risk patients  
 combination therapy (OAC + antiplatelets) in patients with acute vascular disease, 
i.e. recent acute myocardial infarction 
 no OAC in low-risk patients  
 no OAC in patients with reported contraindications to OAC or therapy decline 
(ii) Under-treatment was defined using the following criteria: 
 no OAC (but antiplatelet or no therapy) in moderate or high-risk patients  
 no combination therapy (OAC + antiplatelets) in patients with recent acute 
myocardial infarction 
 no reported contraindications to OAC or therapy decline 
(iii) Over-treatment was defined as follows:  
  OAC in low-risk patients  
  OAC + antiplatelet therapy in patients with no evidence of acute vascular disease 
  OAC in patients with reported contraindications to anticoagulation therapy 
 Antiplatelets in patients with reported contraindications to both OAC and 
antiplatelet therapy 
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Statistical Analysis 
Categorical variables are reported as absolute frequencies and percentages, and continuous 
variables as mean and standard deviation (SD). Baseline characteristics, stroke risk and 
antithrombotic treatment, as well as outcome events were tabulated in relation to the three 
categories (under-treatment, guideline-adherence and over-treatment). For the outcome 
events, confidence intervals (CI) were provided for the proportion of one-year incident 
stroke rates and for the proportion of one-year all-cause mortality rates, respectively. 
 
Multivariable logistic regression analysis was performed to determine the independent 
predictors for one year stroke rates after adjustment for clinically relevant variables: age, 
hypertension, previous stroke, heart failure and antithrombotic treatment (under-
treatment, guideline-adherence [as reference] and over-treatment). For all-cause death 
predictors, the multivariable regression analysis was performed after adjustment for the 
following variables: age, sex, hypertension, diabetes, previous stroke, heart failure, vascular 
disease and antithrombotic treatment. The multivariable analysis was performed separately 
for the whole study population and for patients at high-risk for stroke. All statistical analyses 
were performed using IBM SPSS Statistics (version 21) software (Chicago, Illinois, USA). 
Statistical significance was set at a two-sided P<.05. 
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RESULTS 
Overall, 2259 patients with AF (2.15% of the population) were identified, of which 50.8% 
received guideline-adherent antithrombotic treatment, 36.1% were under-treated and 
13.1% were over-treated. The proportion of women was similar across 3 study groups, at 
46.1% on average. Under-treated patients were older (mean age 77.0 years, standard 
deviation [SD] 11.6) compared to guideline-adherent (75.3, SD 11.9) and over-treated 
subjects (73.0, SD 14.6), while the proportion of those ≥75 years of age was non-significantly 
different between the under-treated (59.8%) and guideline-adherent (60.4%) groups (P=.78) 
(Table 1).  
 
The highest prevalence of heart failure (26.4%), hypertension (65.6%) and diabetes mellitus 
(24.0%) was observed in the guideline-adherent group, whereas previous history of stroke 
(27.4%) was more common in over-treated subjects and least frequent in under-treated 
patients (13.0%). No significant difference was noted with regard to stable and acute 
vascular disease (i.e. acute myocardial infarction) amongst all groups (Table 1). 
 
Thromboembolic Risk and Antithrombotic Treatment 
Stroke risk, as assessed by CHA2DS2-VASc score (mean, SD), was 3.4 (1.6) for under-
treatment, 3.6 (1.7) for guideline-adherence and 3.4 (2.3) for over-treatment, respectively 
(Table 1). In the guideline-adherent cohort, 79.3% patients were prescribed OAC (alone or in 
combination with antiplatelets), 7.1% antiplatelet therapy and 13.6% were untreated (no 
antithrombotic therapy). OAC was reported as contraindicated in 5.7% and declined in 9.9%. 
In the under-treated cohort, 74.1% received antiplatelet therapy and 25.9% were not 
treated, whereas in the over-treated group 57.5% patients were given OAC (either alone or 
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in combination with antiplatelets), 42.5% antiplatelets alone, and 41.2% had reported 
contraindications to OAC (Table 1). Of 1080 patients who received OAC, 1050 (97.2%) were 
given a vitamin K antagonist (predominantly warfarin) and 30 (2.8%) a non-vitamin K OAC 
(NOAC). Antithrombotic drug choice in relation to guideline adherence and risk of stroke is 
summarized in Figure 1. 
 
Clinical Outcomes 
At one year, there were 32 incident strokes (3.9%, 95% confidence interval [CI], 2.8-5.5) for 
the under-treated group, 20 strokes (1.7%, 95% CI, 1.1-2.7) for those guideline-adherent 
and 15 strokes (5.1%, 95% CI, 3.1-8.2) for those over-treated; corresponding all-cause 
mortality rates were 14.1% (95% CI, 11.9-16.7), 7.1% (95% CI, 5.7-8.7) and 6.1% (95% CI, 3.9-
9.4), respectively. The reasons for cardiovascular deaths were similar across the 3 study 
groups, except that significantly more fatal strokes were observed among those under-
treated (1.1%, n=9) versus guideline-adherent (0.2%, n=2, P=.007). Details of one-year 
outcomes in relation to guideline adherence (or not) for antithrombotic treatment are 
summarized in Table 2. 
 
Clinical outcomes by thromboembolic risk profile and applied antithrombotic therapies as 
per 2014 NICE guidelines3 are shown in Table 3. Of 67 (3.0%) acute strokes, 66 (98.5%) were 
observed in high-risk patients (CHA2DS2-VASc ≥2). For the high-risk cohort, one-year stroke 
rates were 4.5% (95% CI, 3.2-6.3) for under-treatment, 1.9% (95% CI, 1.2-2.9) for guideline-
adherence, and 7.2% (95% CI, 4.4-11.6) for over-treatment; corresponding all-cause, one-
year mortality rates were 16.1% (95% CI, 13.6-19.0), 8.0% (95% CI, 6.5-9.8), and 8.2% (95% 
CI, 5.2-12.7), respectively. One stroke event was noted in a low-risk patient, a man classified 
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as guideline-adherent (off anticoagulation). No one-year stroke events or deaths were 
observed in patients at moderate risk of stroke (Table 3). 
 
Antithrombotic Treatment in Patients with Acute Stroke 
Antithrombotic drug choice in patients who experienced an acute stroke during 12-month 
observation is presented in Supplemental Figure 1, separately for the entire study 
population (Panel A) and the high-risk cohort (Panel B). Of the 32 high-risk patients who 
were under-treated and had acute stroke, 23 were on antiplatelet therapy and 9 remained 
untreated. Of the 19 high-risk and guideline-adherent patients who had incident stroke, 18 
received OAC alone and 1 OAC in combination with antiplatelets, whereas for the high-risk 
and over-treated subjects, 10 were on combination therapy (OAC + antiplatelets), 1 received 
OAC alone and 4 antiplatelet monotherapy (Panel B). 
 
Predictors of Stroke and Death 
On multivariable analysis for the entire population, non-guideline adherence to 
antithrombotic therapy was associated with a significant increase in one-year stroke rate for 
those under-treated (odds ratio [OR] 2.18, 95% CI, 1.23-3.87, P=.008) and over-treated (OR 
2.07, 95% CI, 1.03-4.16, P=.04). For one-year all-cause mortality, non-guideline adherence 
was associated with a significant increase in mortality for those under-treated (OR 1.57, 95% 
CI, 1.13-2.18, P=.007).  
 
For high-risk patients, both under- and over-treatment were associated with a significant 
increase in one-year stroke rates (OR 2.32, 95% CI, 1.30-3.14, P=.005 and OR 2.28, 95% CI, 
1.12-4.63, P=.02, respectively), whereas under-treatment was also associated with 
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significant increase in one-year all-cause mortality (OR 1.59, 95% CI, 1.14-2.21, P=.006) 
(Table 4). 
 
 
DISCUSSION 
The principal findings of this study are that although nine in ten AF patients managed in 
general practice are at high risk for acute stroke, only half are prescribed anticoagulation in 
line with current guideline recommendations. Most importantly, guideline-adherent 
antithrombotic treatment significantly reduced stroke rates and improved survival.    
 
This study provides important insights into stroke risk profile and stroke prevention 
strategies in a contemporary, non pre-selected primary care AF population in the United 
Kingdom. First, at least one non-gender related risk factor for stroke (by CHA2DS2-VASc 
scheme and using GRASP-AF tool) was captured in 92.5% AF all-comers. Contemporary 
global registry data, confined to new onset AF only, demonstrate a very similar incidence, at 
6.8%,6 while European registries recruiting AF patients managed by cardiologists indicate 
even lower prevalence of lone AF, at 3.9%.5 These observations highlight the clinical 
relevance of careful and repeated screening for even a single stroke risk factor in every AF 
patient, with primary physicians playing a pivotal role, given that stroke risk is not static but 
changes (increases) over time.2,20 Importantly, once the diagnosis of truly low risk has been 
proven, anticoagulation may be omitted.3,4 Indeed, of 170 low-risk patients (CHA2DS2-
VASc=0 in men and 1 in women) in the present analysis, only a single case of stroke 
occurred. However, nearly one third of such low-risk patients were unnecessarily prescribed 
OAC. Similar overuse of stroke prevention therapies among patients with no stroke risk 
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factors has been noted by previous reports.6,8 Importantly, current AF guidelines do not 
recommend treatment of low-risk patients as there is no evidence of benefit, but there may 
be increased risk of harm.3,4 
 
Second, none of the 154 men at moderate risk of stroke (CHA2DS2-VASc=1) in the present 
study suffered an acute stroke or died during the 12-month observation period. Our study 
was not powered to analyze whether the use of, or absence of, OAC affects outcomes in 
patients with only one risk factor for stroke. Annual stroke rates in untreated patients with 
only 1 risk factor for stroke (beyond sex) do vary amongst studies.21–23 A recent Markov 
decision model suggests that stroke risk >1.7%/year and >0.9%/year warrants 
anticoagulation with warfarin and NOACs, respectively.24 However, this model did not 
consider quality of anticoagulation control amongst warfarin users; with good quality 
control, the 1.7%/year treatment threshold may even be lower.25 For example, 
stroke/systemic thromboembolic events and mortality are high even in patients with only 
one stroke risk factor and despite OAC use.25 Importantly, these event rates were 
significantly but inversely associated with time spent in therapeutic range (TTR), ranging 
from 3.5% in lowest TTR quartile to only 0.7% in the highest TTR quartile. Of note, current 
AF guidelines already recommend OAC use as a default therapy (whether with an NOAC or 
warfarin with TTRs as high as possible) in all AF patients unless truly low-risk is shown.2–4 
 
Third, we show herein that neither underuse nor overuse of antithrombotic therapy is 
beneficial for high-risk patients (CHA2DS2-VASc ≥2). One-year stroke rates were lowest, at 
1.9%, for guideline-adherence, whereas the corresponding rates for under- and over-
treatment were 4.5% and 7.2%, respectively. Also, all-cause mortality was 2-fold higher in 
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those non-adherent with recommendations. These findings highlight importance of strict 
compliance with guideline recommendations (in this case, NICE) in real-life clinical practice.3  
 
Previous studies have also reported that guideline adherence is associated with better 
outcomes in AF patients.14–17 In contrast to our study these patients were managed either 
by cardiologists,14–16 or internal medicine specialists,17 where the prevalence of in-patients 
and participating university centers were high, as was the overall OAC uptake (up to 80%).16 
In addition, none of these studies considered contraindications to OAC or therapy decline 
(8.3% and 5.0%, respectively in our study), and only the EuroObservational Research 
Programme-Atrial Fibrillation (EORP-AF) Pilot General Registry corrected the definition of 
guideline adherence for the presence of acute vascular disease.16 Importantly, definition of 
clinical outcomes in prior studies did vary considerably. For example, the EORP-AF registry 
did not show significantly lower rates of stroke alone for guideline-adherence (as shown in 
the present analysis), but for a combined thromboembolic endpoint that comprised of 
stroke, transient ischemic attack, acute coronary syndrome, percutaneous coronary 
intervention, cardiac arrest, peripheral embolism and pulmonary embolism.16  
 
Moreover, our study supports several important points regarding antithrombotic drug 
choice. First, aspirin is not effective and should not be used for stroke prevention in AF.3,4 
One-year stroke rates in high-risk patients were even higher in those under-treated with 
antiplatelets versus no treatment. This is alarming, given that more than one third of eligible 
patients in the present analysis were not offered OAC, which not only significantly reduced 
stroke rates, but was also a life-saving treatment. Importantly, more recent data indicate 
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that overall mortality reduction with an OAC even exceeds the reduction of stroke-related 
deaths only.26  
 
Second, one in ten high-risk patients were over-treated, either with an OAC (in combination 
with antiplatelets or alone) or with antiplatelets (reported contraindications to both OAC 
and antiplatelet therapy). Importantly, only a few AF patients with recent acute myocardial 
infarction were guideline-adherent on combination therapy, while the majority received 
either antiplatelet therapy only (under-treated cohort) or a combination therapy despite 
reported contraindications (over-treated cohort). Both regimens resulted in an excess in 
stroke rates, but allocation of many patients with vascular disease to the over-treated 
cohort creates a bias of their overall increased risk compared to guideline-adherence. Even 
assuming that contraindications to OAC might have been over-estimated by physicians, and 
some of these patients could actually be categorized as guideline-adherent, stroke rates of 
these patients would still remain high.  
 
Limitations and Strengths 
The major limitation of this analysis is lack of overall bleeding risk and outcomes. Indeed, 
the GRASP-AF tool used for data collection in Darlington Registry does not collect data on 
bleeding risk or events. Consequently, fatal and non-fatal hemorrhages were available only 
for patients with outcome events (stroke and death). Despite this limitation we think that 
our findings are of clinical relevance for variety of reasons. First, GRASP-AF tool is part of the 
cornerstone National Health Service (NHS) quality improvement programs, which was 
primarily designed and implemented into practice to help primary care physicians tackle the 
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nation’s biggest killer, i.e. stroke. Even more importantly, use of the GRASP-AF tool has been 
previously described as a means that could help prevent strokes in AF patients.18 
 
Second, guideline recommendations on stroke prevention in AF highlight that bleeding risk 
per se should not be a reason to preclude or withhold stroke prevention strategies in at risk 
for stroke AF patients.3,4 Indeed, absolute contraindications to OAC are rare and if a patient 
truly cannot receive any of the available OACs, despite being at high risk for stroke, other 
options of stroke prevention could be considered (i.e. left atrial appendage exclusion).3,4 If 
contraindications to OAC are not genuine, the priority should be correction of any 
potentially reversible risk factors for bleeding, but not withholding OAC use simply on a 
perceived high bleeding risk score.27 
 
Third, stroke and bleeding risk factors commonly overlap.28 Thus, patients at highest risk for 
bleeding are usually also at highest risk for stroke, but the net clinical benefit of 
anticoagulation is positive and even greater in patients with both high stroke and bleeding 
risks,29 i.e. patients with frequent comorbid disease, very elderly and frail,11 30 or even those 
who have already bled (even intracranially).31 Indeed, in contrast to stroke rates we did not 
observe any difference in hemorrhagic strokes or intracranial bleeds amongst all three study 
groups. 
 
Fourth, patients’ views and preferences are also of great importance. Indeed, patients often 
view a stroke “as a fate worse than death”, and may accept 4 major bleeds just to avoid one 
disabling stroke.9 Thus, as the guideline-recommended decision making on OAC prescribing 
is based on positive net clinical benefit when balancing the risk of stroke against the risk of 
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bleeding complications (intracranial hemorrhage),24 we do not think that providing the 
overall bleeding events (in addition to reported non-fatal intracranial bleeds and fatal 
hemorrhages) would substantially change our conclusions. 
 
Our definition of adherence to guidelines may be inconsistent with previous papers, which 
reported absolute numbers/percentages of OAC use in AF patients, and thus failed to reflect 
their “real-life eligibility” for anticoagulation (in particular, including patient’s views and 
preferences). By doing so, previous reports showed more the impact of OAC use on 
outcomes rather than the impact of guideline-adherence on outcomes. Indeed, exclusion of 
contraindications to OAC or therapy decline, assumes that 100% patients must be given OAC 
(no exceptions), while the real-life data show that 12% of AF patients (so called "medication 
averse") refuse anticoagulation, even if the therapy were 100% effective for stroke 
prevention.9 
We have assessed the quantity, but not quality of anticoagulation, as neither international 
normalized ratios nor TTR values were available. Although this registry covered a broad 
population of over 100,000 patients, it was confined to one UK region only, which may limit 
the generalizability of the findings. Because patient-specific data were analyzed more in 
detail only in patients with outcome events, baseline characteristics of the entire study 
population are limited. However, lack of patient selection allowed for evaluation of 
antithrombotic treatment patterns and outcomes in low- and moderate-risk cohorts. Unlike 
other studies, we have also used only “hard” endpoints, which were confirmed by cerebral 
imaging and adjudicated. Nonetheless, we could not establish the cause of death with 
certainty in overall 45 patients (21.0% of all deaths), as death certificates could not be 
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retrieved. Thus, multivariable analysis of cardiovascular mortality predictors was not 
possible. 
We have based our definition of guideline adherence on the 2014 NICE guideline 
recommendations (which are applicable to our UK-based study),3 which has similarity to the 
2012 focused update of European Society of Cardiology guidelines on AF.32 Our study 
validates the “real world” application of these guidelines and the potential impact on stroke 
and mortality in AF patients. 
 
CONCLUSION 
Despite nine in ten AF patients being at high risk for stroke, only half of eligible patients are 
prescribed anticoagulation in accordance with current guidelines. Guideline-adherent 
antithrombotic treatment significantly reduces the risk of stroke and improves survival at 
one year. 
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FIGURE LEGENDS 
 
Figure  1  Antithrombotic Treatment in Relation to Guideline Adherence and Risk of Stroke 
Panel A   Low risk (CHA2DS2-VASc=0 in men and 1 in women)                                                 
Panel B   Moderate risk (CHA2DS2-VASc=1 in men) 
Panel C   High risk (CHA2DS2-VASc ≥2) 
 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, 
stroke/transient ischemic attack (TIA), vascular disease, age 65-74 years, sex category 
(female); OAC = oral anticoagulant 
 
 
Supplemental Figure 1  One-Year Stroke Rates in Relation to Antithrombotic Guideline 
Adherence 
Panel A   Entire population (unselected study cohort)                                        
Panel B   High-risk cohort (CHA2DS2-VASc ≥2) 
 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, 
stroke/transient ischemic attack (TIA), vascular disease, age 65-74 years, sex category 
(female); OAC = oral anticoagulant. 
Some percentages may not sum up to total due to rounding. 
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Table 1 Baseline Characteristics of the Patient Population 
 
 
All  Under-treatment     Guideline-adherence Over-treatment  
 2259 (100) 816 (36.1) P valuea  1147 (50.8) 296 (13.1) P valuea  
Demographics       
Females 1041 (46.1) 390 (47.8) .28 520 (45.3) 131 (44.3) .74 
Age, years, mean (SD) 75.6 (12.3) 77.0 (11.6) .001 75.3 (11.9) 73.0 (14.6) .006 
<65 years 367 (16.2) 100 (12.3) .05 177 (15.4) 90 (30.4) <.001 
65-74 years 554 (24.5) 228 (27.9) .06 277 (24.1) 49 (16.6) .005 
≥75 years 1338 (59.2) 488 (59.8) .78 693 (60.4) 157 (53.0) .02 
Medical history       
Heart failure 514 (22.8) 148 (18.1) <.001 303 (26.4) 63 (21.3) .07 
Hypertension 1404 (62.2) 494 (60.5) .02 753 (65.6) 157 (53.0) <.001 
Diabetes  490 (21.7) 150 (18.4) .003 275 (24.0) 65 (22.0) .47 
Previous stroke 428 (18.9) 106 (13.0) <.001 241 (21.0) 81 (27.4) .02 
Previous hemorrhagic stroke 17 (0.8) 3 (0.4) .46 7 (0.6) 7 (2.4) .006 
Vascular disease 389 (17.2) 156 (19.1) .05 180 (15.7) 53 (17.9) .36 
Acute myocardial infarction 152 (6.7) 53 (6.5) .97 74 (6.5) 25 (8.4) .23 
Thromboembolic risk by CHA2DS2-VASc       
Mean score (SD) 3.5 (1.8) 3.4 (1.6) <.001 3.6 (1.7) 3.4 (2.3) .02 
Low risk (score=0 in men and 1 in 
women) 
170 (7.5) 0 <.001 86 (7.5) 84 (28.4) <.001 
Moderate risk (score=1 in men) 154 (6.8) 101 (12.4) <.001 49 (4.3) 4 (1.3) .02 
High risk (score ≥2) 1935 (85.7) 715 (87.6) .68 1012 (88.2) 208 (70.3) <.001 
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a
versus guideline-adherent group. 
Data are presented as n (%) or mean (SD). 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular disease, age 65-74 years, sex 
category (female); NICE = National Institute for Health and Care Excellence; OAC = oral anticoagulant; SD =  standard deviation. 
 
Antithrombotic treatment       
None 367 (16.2) 211 (25.9) <.001 156 (13.6) 0 <.001 
Antiplatelets  812 (35.9) 605 (74.1) <.001 81 (7.1) 126 (42.5) <.001 
OAC 971 (43.0) 0 <.001 906 (79.0) 65 (22.0) <.001 
OAC + antiplatelets 109 (4.8) 0 .09 4 (0.3) 105 (35.5) <.001 
Oral anticoagulation       
Contraindicated 187 (8.3) 0 <.001 65 (5.7) 122 (41.2) <.001 
Declined 113 (5.0) 0 <.001 113 (9.9) 0 <.001 
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Table 2 One-Year Outcomes in Relation to Antithrombotic Treatment According to the 2014 NICE Guidelines3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
versus guideline-adherent group. 
All outcome events were confirmed by cranial imaging (CT or MRI, for acute strokes) and adjudicated. 
CI = confidence interval; CT = computer tomography; MRI = magnetic resonance imaging; NICE = National Institute for Health and Care Excellence; PE = pulmonary 
embolism; STE = systemic thromboembolism.  
 
 
All 
  
Under-treatment  
 
 Guideline-adherence 
 
Over-treatment  
Outcome events n (%) n (%)  [95% CI] P valuea n (%)  [95% CI] n (%)  [95% CI] P valuea 
       
Stroke 67 (3.0) 32 (3.9)  [2.8-5.5] .003  20 (1.7)  [1.1-2.7] 15 (5.1)  [3.1-8.2] <.001 
Ischemic 62 (2.7) 30 (3.7)  [2.6-5.2] .003 18 (1.6)  [1.0-2.5] 14 (4.7)  [2.8-7.8] .001 
Hemorrhagic  5 (0.2) 2 (0.2)  [0.1-0.9] .73 2 (0.2)  [0.1-0.6] 1 (0.3)  [0.1-1.9] .58 
       
Death       
All-cause 214 (9.5) 115 (14.1)  [11.9-16.7]  <.001 81 (7.1)  [5.7-8.7] 18 (6.1)  [3.9-9.4]  .55 
Cardiovascular       
Cardiac death 14 (0.6) 8 (1.0)  [0.5-1.9] .14 5 (0.4)  [0.2-1.0] 1 (0.3)  [0.1-1.9] .82 
Heart failure 24 (1.1) 11 (1.3)  [0.8-2.4] .67 13 (1.1)  [0.7-1.9] 0 .07 
Stroke 11 (0.5) 9 (1.1)  [0.6-2.1]
 
.007 2 (0.2)  [0.1-0.6] 0 .47 
PE or STE 3 (0.1) 1 (0.1)  [0.0-0.7] .77 2 (0.2)  [0.1-0.6] 0 .47 
Intracranial bleeding 5 (0.2) 3 (0.4)  [0.1-1.1] .40 2 (0.2)  [0.1-0.6] 0 .47 
Non-cardiovascular       
Bleeding non-cerebral 3 (0.1) 1 (0.1)  [0.0-0.8] .81 1 (0.1)  [0.0-0.5] 1 (0.3)  [0.1-1.9] .30 
Cancer  42 (1.9) 15 (1.8)  [1.1-3.0] .65 18 (1.6)  [1.0-2.5]  9 (3.0)  [1.6-5.7] .10 
Other 67 (3.0) 40 (4.9)  [3.6-6.6] <.001 21 (1.8)  [1.2-2.8] 6 (2.0)  [0.9-4.4]  .82 
Unknown 45 (2.0) 27 (3.3)  [2.3-4.8] .007 17 (1.5)  [0.9-2.4]  1 (0.3)  [0.1-1.9]  .11 
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Table 3 One-Year Outcomes in Relation to Stroke Risk and Guideline Adherence in Antithrombotic Treatment  
 
a
versus guideline-adherent group. 
Data are presented as n (%) [95% CI]. 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular disease, age 65-74 years, sex 
category (female); CI = confidence interval. 
 
 
 
Stroke risk  
by CHA2DS2-VASc score 
Outcomes All Under-treatment 
 
 
P value
a 
Guideline-adherence Over-treatment 
 
 
P value
a 
        
Low risk   
(score 0 in men and 1 in women) 
 n=170 n=0  n=86 n=84  
 Stroke 1 (0.6) -  1 (1.2)  [0.2-6.3] 0  
 All-cause death 1 (0.6) -  0 1 (1.2)  [0.2-7.4]  
        
Moderate risk  (score 1 in men)  n=154 n=101  n=49 n=4  
 Stroke 0 0  0 0  
 All-cause death 0 0  0 0  
        
High risk  (score ≥2)  n=1935 n=715  n=1012 n=208  
 Stroke 66 (3.4) 32 (4.5)  [3.2-6.3]    .002 19 (1.9)  [1.2-2.9]  15 (7.2)  [4.4-11.6] <.001 
 All-cause death 213 (11.0) 115 (16.1)  [13.6-19.0]  <.001 81 (8.0)  [6.5-9.8] 17 (8.2)  [5.2-12.7]   .93 
Mazurek32 
 
Table 4 Multivariable Regression Analysis for One Year Stroke and Death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entire population 
OR (95% CI) 
 
 
P value 
 
High-risk cohorta  
OR (95% CI) 
 
 
P value 
     
Stroke     
Age (per 1 y increase) 1.05 (1.02-1.08) .001 1.04 (1.01-1.07) .006 
Hypertension 0.92 (0.54-1.58) .76 0.89 (0.52-1.53) .67 
Previous stroke 5.20 (3.10-8.74) <.001 4.96 (2.95-8.36) <.001 
Heart failure 1.34 (0.76-2.36) .32 1.31 (0.74-2.32) .35 
Antithrombotic therapy     
Under-treatment 2.18 (1.23-3.87) .008 2.32 (1.30-3.14) .005 
Guideline-adherence 1.0 (ref.)  1.0 (ref.)  
Over-treatment 2.07 (1.03-4.16) .04 2.28 (1.12-4.63) .02 
     
All-cause death      
Age (per 1 y increase) 1.10 (1.08-1.13) <.001 1.10 (1.08-1.13) <.001 
Female sex 1.24 (0.89-1.72) .20 1.18 (0.85-1.64) .32 
Hypertension 0.96 (0.69-1.34) .81 0.94 (0.67-1.32) .73 
Diabetes 1.51 (1.07-2.14) .02 1.50 (1.06-2.12) .02 
Previous stroke 0.82 (0.56-1.21) .32 0.82 (0.55-1.20) .30 
Heart failure 1.96 (1.41-2.72) <.001 1.93 (1.39-2.69) <.001 
Vascular disease 2.86 (2.10-4.00) <.001 2.80 (2.00-3.91) <.001 
Antithrombotic therapy     
Under-treatment 1.57 (1.13-2.18) .007 1.59 (1.14-2.21) .006 
Guideline-adherence 1.0 (ref.)  1.0 (ref.)  
Over-treatment 0.74 (0.43-1.30) .29 0.71 (0.40-1.25) .24 
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a
High-risk cohort = CHA2DS2-VASc ≥2. 
ATT = antithrombotic treatment; CI = confidence interval; OR = odds ratio; ref = reference; y = year.  
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